Cristin-resultat-ID: 1479222
Sist endret: 22. september 2017 14:12
NVI-rapporteringsår: 2017
Vitenskapelig artikkel

The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004–2015

  • Pål Gjerden
  • Jørgen Gustav Bramness
  • Ingunn Fride Tvete og
  • Lars Slørdal


European Journal of Clinical Pharmacology
ISSN 0031-6970
e-ISSN 1432-1041
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2017
Volum: 73
Hefte: 9
Sider: 1173 - 1179


Scopus-ID: 2-s2.0-85020492911

Beskrivelse Beskrivelse


The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004–2015


Purpose The antipsychotic agent quetiapine was introduced in Norway in 2003. We have assessed changes in dispensed prescriptions, including dosing, of quetiapine in Norway from 2004 to 2015. Methods Data on the sales of antipsychotics and antidepressants were drawn from the Norwegian Prescription Database. A total of 47,474 outpatients filled 195,622 prescriptions of quetiapine. Reimbursement codes, use of antipsychotics or antidepressants 12 months prior to the first prescription of quetiapine and estimated mean volume used measured as defined daily doses (DDDs) per day were used as proxies for diagnoses. We conducted a regression analysis with DDD per day as a function of possible explanatory variables. Results The number of users filling at least two prescriptions of quetiapine per year increased from 584 in 2004 to 8506 in 2015 and the mean dose declined from 1.58 DDD per day (SD 8.00) to 0.48 DDD per day (SD 2.27). The latter is much lower than recommended for treatment of psychoses. In 2015, 60.1% of the 8506 quetiapine users did not seek reimbursement for the treatment of a major psychiatric disorder and only 2.6% of the patients were prescribed 1 DDD or more per day and reimbursed in accordance with the drug’s primary indication, psychosis. A reported diagnosis of psychosis was not associated with higher quetiapine doses. Conclusions In 2015, the pattern of quetiapine dispensing in Norway most likely reflects predominant off-label use. This is unsettling considering poorly documented effects in non-psychotic disorders, profound side effects, significant toxicity and growing concern regarding abuse.


Pål Gjerden

  • Tilknyttet:
    ved Psykisk helsevern og rusbehandling – klinikk ved Sykehuset Telemark HF

Jørgen Gustav Bramness

  • Tilknyttet:
    ved Div Psykisk helsevern ved Sykehuset Innlandet HF

Ingunn Fride Tvete

  • Tilknyttet:
    ved Statistisk analyse, maskinlæring og bildeanalyse SAMBA ved Norsk Regnesentral

Lars Slørdal

  • Tilknyttet:
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet
  • Tilknyttet:
    ved Laboratoriemedisinsk klinikk ved St. Olavs Hospital HF
1 - 4 av 4